GeneGlobe ID: JHS-002Z | Cat. No.: | QIAseq RNA Fusion XP Panels

RNA Fusion XP Solid Tumor Panel

Kit containing ALL reagents (except indexes) for fusion and gene expression profiling by digital RNAseq
Select a variant to see the price

Product Specification

Target List
Bone Cancer
Askins Tumors​
ERG, EWSR1, FLI1, FUS
Ewing's Sarcomas​
ERG, ETV1, ETV4, EWSR1, FEV, FLI1, FUS, NFATC2, SMARCA5
Giant Cell Tumors​
EWSR1, FLI1
Mesenchymal Chondrosarcomas​
CDX1, HEY1, IRF2BP2, NCOA2
Myxoid Chondrosarcomas​
EWSR1, NR4A3 (NOR1), TAF15, TCF12, TFG
Brain Cancer
Gliomas​
BRAF, CLCN6, FAM131B, FGFR1, FGFR3, FIP1L1, GNAI1, GOPC, MKRN1, MYB, PDGFRA, PRKCB, RAF1, RNF130, ROS1, SRGAP3, TACC1, TACC3
Neuroblastomas​
EWSR1, FLI1
Pilocytic Astrocytomas​
CLCN6, FAM131B, GNAI1, MKRN1, RNF130, SRGAP3, TACC1
Other Brain Cancers​
EWSR1, FLI1, NAB2, PDGFRA, PRKCA, STAT6
Breast Cancer
Carcinomas​
BRD3, DAZL, ETV6, FGFR1, MAST1, MAST2, NTRK3, PIK3CA (p110-alpha), RAF1, TBL1XR1, ZC3H7B, ZNF703
Ductal Carcinomas​
DAZL, ETV6, NTRK3
Other Breast Cancers​
AKT3, ESR1 (ERα), NOTCH2
Colorectal Cancer
Adenocarcinomas​
ETV6, INSR, NTRK1, NTRK3, TCF7L2, TPM3, VTI1A
Kidney Cancer
Carcinomas​
ALK, ASPSCR1, PRCC, TFE3, VCL
Clear Cell Sarcomas​
TERT
Mesoblastic Nephromas​
ETV6, NTRK3
Renal Cell Carcinomas​
TFEB, VCL
Liver Cancer
Cholangiocarcinomas​
CCDC6, FGFR2, TACC3
Hepatocellular Carcinomas​
PKN1
Lung Cancer
Acinar Adenocarcinomas​
ALK, CD74, EML4, HIP1, KIF5B, ROS1, SDC4
Adenocarcinomas​
ALK, BAIAP2L1, BCL11A, BRAF, CCDC6, CD74, CUX1, EML4, EZR, FGFR2, FGFR3, GCC2, GOPC, HIP1, HLA-DRB1, KIAA1217, KIF5B, KLC1, LRIG3, MET, MPRIP, NCOA4, NRG1 (HGL), NTRK1, NTRK2, PBX1, PRKCB, RET, ROS1, SDC4, SLC34A2, SND1, STARD3NL, STRN, TACC3, TCF3, TFG, TPM3, TPR, TRIM24, TRIM33
Bronchioloalveolar Adenocarcinomas​
ALK, EML4, KLC1, PBX1, ROS1, SDC4, TCF3
Inflammatory Myofibroblastic Tumors​
ALK, CD74, EML4, EZR, GOPC, LRIG3, PPFIBP1, ROS1, SDC4, SLC34A2, TPM3
Invasive Mucinous Adenocarcinomas​
ALK, CD74, EML4, NRG1 (HGL), SLC3A2
Mixed Adenosquamous Carcinomas​
ALK, EML4, KIF5B, RET
Mucoepidermoid Carcinomas​
ALK, CRTC1, EML4, MAML2
Non-Small Cell Carcinomas​
ALK, BCL11A, CCDC6, CD74, CUX1, EGFR (ERBB1), EML4, EZR, GCC2, GOPC, HIP1, KIAA1217, KIF5B, KLC1, LRIG3, NCOA4, RET, ROS1, SDC4, SLC34A2, STRN, TFG, TPM3, TPR, TRIM33
Non-Small Cell Lung Cancers (NSCLC)​
ALK, BAG4, BAIAP2L1, BCL11A, CCDC6, CD74, CLIP4, CUX1, DNAH5, EGFR (ERBB1), EML4, ETV6, EZR, FER, FGFR1, FGFR3, GCC2, GLRX5, GOPC, HIP1, HLA-DRB1, IRF2BP2, KIAA1217, KIF5B, KLC1, LRIG3, MAN2A1, MET, MPRIP, NCOA4, NRG1 (HGL), NTRK1, NTRK3, RAD51, RET, ROS1, RUNX1 (AML1), SDC4, SLC34A2, SLC3A2, SQSTM1, STRN, TACC3, TFG, TPM3, TPR, TRA2B, TRIM33, VSNL1
Squamous Cell Carcinomas (SCC)​
ALK, BAIAP2L1, CD74, EML4, FGFR2, FGFR3, FGR, HIP1, KIF5B, NRG1 (HGL), PKN1, PRKCA, PRKCB, RET, TACC3
Other Carcinomas​
ALK, BRD4, EML4, NUTM1
Other Lung Cancers​
ARL17A, BAG4, BAIAP2L1, CCDC6, CD74, CUX1, EZR, FGFR1, FGFR3, GOPC, IRF2BP2, KANSL1, KIAA1217, KIF5B, LRIG3, MPRIP, NCOA4, NRG1 (HGL), NTRK1, NUTM1, PTPRK, RET, ROS1, RSPO3, SDC4, SLC34A2, SLC3A2, SQSTM1, TACC3, TPM3, TPR, TRIM33, WHSC1L1
Lymphoma
Acute Lymphoblastic Lymphomas​
CREBBP (CBP), KMT2A, MLLT10, MYC, P2RY8, PRDM16, STIL
Anaplastic Large Cell Lymphomas​
ADGRG7, ALK, ATIC, CLTC, MSN, MYC, NPM1, TFG, TPM3, TPM4
Angioimmunoblastic T Cell Lymphomas​
CD28, CTLA4, FIP1L1, PDGFRA
Burkitt Lymphomas​
BCL6, MYC, PBX1, TCF3
Diffuse Large B Cell Lymphomas (DLBCL)​
ALK, BCL11A, BCL6, CCND3, CIITA, CLTC, IGLL5, MAPK13 (p38delta), MYC, NPM1, PIM1, REL, SQSTM1, TBL1XR1, TOMM40, TP63
Follicular Lymphomas​
AFF3, BCL2, BCL6, CIITA, MYC, TBL1XR1, TP63
Granulocytic Sarcomas​
RUNX1 (AML1), RUNX1T1
Hodgkin Lymphomas​
ALK, CIITA, JAK2, NPM1, SEC31A
Inflammatory Myofibroblastic Tumors​
ALK, CARS, DCTN1
Lymphoblastic Lymphomas​
BCR, ETV6, FGFR1, NOTCH1, PBX1, PDGFRB, TERT
Lymphoblastic T Cell Lymphomas​
BCR, ETV6, FGFR1, FIP1L1, LYN, PDGFRA
Mantle Cell Lymphomas​
CCND3, MYC
Mediastinal Large B Cell Lymphomas (MLBL)​
CIITA, PDCD1LG2
Mediastinal Large B-Cell Lymphomas​
CIITA, PDCD1LG2
Mucosa-Associated Lymphoid Tissue (MALT) Lymphomas​
BCL6, BIRC3 (c-IAP2), CCND3, MALT1, MYC
Peripheral T Cell Lymphomas​
ALK, ETV6, FGFR3, ITK, MYO1F, NPM1, S100A7, SYK, TBL1XR1, THAP4, TP63, VAV1
Precursor T Cell Lymphoblastic Lymphomas​
ABL1, JAK2, NUP214, PCM1, SET
T Cell Lymphomas​
ATXN2L, FGFR1, JAK2
Other Lymphomas​
ALK, ATXN2L, BCL6, BIRC3 (c-IAP2), CBFB, CCND1, CCND3, CDK6, CHIC2, CLTC, DEK, DUSP22, EIF4A1, JAK2, KMT2A, MALT1, MKL1, MLF1, MLLT10, NFKB2, NPM1, PRDM16
Ovarian Cancer
Serous Cyst Adenocarcinomas​
AXL, FGR, INSR
Pancreatic Cancer
Acinar Cell Carcinomas​
GATM, HACL1, HERPUD1, SND1, ZSCAN30
Adenocarcinomas​
ACSL3, ACVR2A, AKT3, BRAF, CANT1, DDX5, ELK4, ERG, ESRP1, ETV1, ETV4, ETV5, HNRNPA2B1, KLK2 (hGK-1, hK2), KRAS, NDRG1, PIK3CA (p110-alpha), RAF1, SLC45A3, TBL1XR1, TMPRSS2, UBE2L3
Carcinomas​
BRAF, RAF1
Prostate Cancer
Adenocarcinomas​
ACSL3, ACVR2A, AKT3, BRAF, CANT1, DDX5, ELK4, ERG, ESRP1, ETV1, ETV4, ETV5, HNRNPA2B1, KLK2 (hGK-1, hK2), KRAS, NDRG1, PIK3CA (p110-alpha), RAF1, SLC45A3, TBL1XR1, TMPRSS2, UBE2L3
Glandular Intraepithelial Neoplasia​
ERG, TMPRSS2
Other Carcinomas​
ERG, ETV1, TMPRSS2
Salivary Gland Cancer
Adenomas​
FGFR1, PLAG1
Mucoepidermoid Carcinomas​
CRTC1, MAML2
Warthin Tumors​
CRTC1, MAML2
Other Carcinomas​
ETV6, NTRK3
Other Salivary Gland Cancers​
MYB
Sarcoma
Alveolar Soft Part Sarcomas​
ASPSCR1, TFE3
Angiosarcomas & Epitheliod Haemangioendotheliomas​
CAMTA1, CEP85L, CIC, LEUTX, ROS1, TFE3, YAP1
Askins Tumors​
ERG, EWSR1, FLI1, FUS
Chondrosarcomas​
ACVR2A, CDX1, EWSR1, FN1, HEY1, IRF2BP2, NCOA2, NR4A3 (NOR1), TAF15, TCF12, TFG
Clear Cell Sarcomas​
ATF1, CREB1, EWSR1, FLI1, NUTM2B, YWHAE
Congenital (Infantile) Fibrosarcomas​
ETV6, MET, NTRK3, TFG
Dermatofibrosarcoma Protuberans​
COL1A1, PDGFB
Dermatofibrosarcomas Protuberans​
COL1A1, PDGFB
Desmoplastic Small Round Cell Tumors​
ERG, EWSR1, FLI1, PATZ1, WT1
Endometrial Stromal Sarcomas​
ALK, BCOR, CXorf67, EPC1, FN1, JAZF1, MBTD1, MEAF6, NUTM2A, NUTM2B, PHF1, SUZ12, YWHAE, ZC3H7B
Epithelioid Sarcomas​
CREB3L1, CREB3L2, EWSR1, FUS, KLF17, SS18, SSX1
Ewing's Sarcomas​
CIC, ERG, ETV1, ETV4, EWSR1, FEV, FLI1, FOXO4, FUS, NFATC2, SMARCA5, SP3
Fibrosarcomas​
BRAF, COL1A1, CREB3L1, CREB3L2, EWSR1, FUS, LMNA, NTRK1, PDGFB, TOM1L2
Leiomyosarcomas​
EWSR1, HMGA2, PBX3, WT1
Liposarcomas​
DDIT3 (GADD153, CHOP), EWSR1, FUS, HMGA2, LGR5, NUP107, TERT
Myofibroblastic Sarcomas​
ALK, LMNA, NTRK1, RELA, ROS1, SRF, TFG, TPM3, YWHAE
Myxofibrosarcomas​
CREB3L1, CREB3L2, FUS
Myxoid Chondrosarcomas​
NR4A3 (NOR1), TAF15
Perivascular Epithelioid Cell Tumors (PEComa)​
DVL2, SFPQ, TFE3
Pleomorphic Sarcomas (Malignant Fibrous Histiocytoma)​
CITED2, MED12, PRDM10
Rhabdoid Tumors​
NCOA4, RET
Rhabdomyosarcomas​
CITED2, EWSR1, FLI1, FOXO1, NCOA1, NCOA2, PAX3, PAX7, SRF, TEAD1, VGLL2
Small Round Cell Tumors​
ERG, ETV1, EWSR1, FEV, FLI1, FOXO1, PAX3
Solitary Fibrous Tumors​
NAB2, STAT6
Synovial Sarcomas​
COL6A3, CSF1 (MCSF), S100A10, SS18, SS18L1, SSX1, SSX2, SSX4B
Undifferentiated; Unclassified or Other Sarcomas​
ATF1, BCOR, BRD4, CCNB3, CREM, ERG, ETV4, EWSR1, FGF1, FGFR1, FLI1, FN1, FOXO1, FUS, GLI1, JAZF1, MAML3, MKL2, NPM1, NUTM1, PAX3, PLAG1, POU5F1 (OCT4), RUNX1 (AML1), RUNX1T1, SUZ12, USP6
Skin Cancer
Adnexal Tumors; Hidradenomas​
CRTC1, MAML2
Atypical Spitzoid Tumors​
ALK, TPM3
Benign Melanocytic Nevus​
ALK, BRAF, CEP89, ERC1, FCHSD1, GOLGA5, KIF5B, LSM14A, MYO5A, PPFIBP1, PWWP2A, RET, ROS1, TPM3
Melanomas​
AGK, ATF1, BRAF, CREB1, EWSR1, FCHSD1, FGR, PAPSS1, TRIM24
Spitzoid Melanomas​
CEP89, LSM14A, MYO5A, PPFIBP1, PWWP2A
Soft Tissue Cancer
Clear Cell Sarcomas​
ATF1, EWSR1
Congenital (Infantile) Fibrosarcomas​
ETV6, NTRK3
Desmoplastic Small Round Cell Tumors​
ERG, EWSR1
Endometrial Stromal Sarcomas​
ALK, FN1
Epithelioid Sarcomas​
SS18, SSX1
Inflammatory Myofibroblastic Tumors​
ALK, ATIC, CARS, CLTC, DCTN1, PPFIBP1, RANBP2, SEC31A, TPM3, TPM4
Leiomyosarcomas​
EWSR1, WT1
Liposarcomas; Myxoid-Round Cell​
DDIT3 (GADD153, CHOP), EWSR1
Liposarcomas; Pleomorphic​
DDIT3 (GADD153, CHOP), FUS
Rhabdoid Tumors​
NCOA4, RET
Rhabdomyosarcomas​
FOXO1, PAX3, PAX7
Sarcomas​
ETV4, EWSR1
Small Round Cell Tumors​
ETV1, EWSR1, FEV, FLI1
Solitary Fibrous Tumors​
NAB2, STAT6
Synovial Sarcomas​
SS18, SSX2
Other Fibrosarcomas​
COL1A1, PDGFB
Thyroid Cancer
Adenoma-Nodule-Goitre​
CCDC6, NCOA4, PAX8, PPARG, PRKAR1A, RET
Anaplastic Carcinomas​
ALK, CCDC6, NCOA4, RET, STRN
Follicular Carcinomas​
PAX8, PPARG
Hurthle Cell Carcinomas​
CCDC6, NCOA4, RET
Mucoepidermoid Carcinomas​
CRTC1, MAML2
Papillary Carcinomas​
AGK, AKAP9, ALK, BRAF, CCDC6, EML4, ERC1, ETV6, GOLGA5, HOOK3, KTN1, NCOA4, NTRK1, NTRK3, PAX8, PCM1, PPARG, PRKAR1A, RET, STRN, TFG, TPM3, TRIM24, TRIM27, TRIM33
Urinary Tract Cancer
Endometrial Carcinomas​
INSR, PIK3CA (p110-alpha)
Transitional Cell Carcinomas​
BAIAP2L1, FGFR3, TACC3
Other Solid Tumors
Midline Carcinomas​
BRD3, BRD4, NUTM1, WHSC1L1
Squamous Cell Carcinomas (SCC)​
MAST2
Other Solid Tumors​
ARHGAP26, BRD3, INSR, MAST2, MSMB, MUSK, NUMBL, NUTM1, PDGFRB, RSPO2, THADA
Commercial Control Samples
ALK, BAIAP2L1, BRAF, CCDC6, CD74, EGFR (ERBB1), EML4, ERG, ETV6, FGFR3, KIF5B, LMNA, MET, NCOA4, NTRK1, NTRK3, PAX8, PPARG, RET, ROS1, SEPT14, SLC34A2, SLC45A3, TACC3, TFG, TMPRSS2, TPM3
Checkpoint Molecules
Inhibitory on Tumor Cells​
CD200, CD274 (PD-L1), CD274 (PD-L1), CD48, CD80, CD86, ITGAV, ITGB3, LGALS9, MICA, MICB, PDCD1LG2, TNFRSF14, VSIR
Stimulatory on Tumor Cells​
CD40 (TNFRSF5), CD40LG, CD48, CD70, CD86, ICOSLG, TNFRSF9, TNFSF14, TNFSF4 (OX40L), TNFSF9
Inhibitory on T Cells​
BTLA, CD160, CD200R1, CD244, CD274 (PD-L1), CD274 (PD-L1), CD28, CTLA4, HAVCR2, KLRC1, LAG3, LILRB1, LILRB3, PDCD1 (PD1), PDCD1 (PD1), VSIR
Stimulatory on T Cells​
CD244, CD27 (TNFRSF7), CD28, CD40 (TNFRSF5), CD40LG, ICOS, TNFRSF14, TNFRSF18, TNFRSF4 (OX40), TNFRSF9, TNFSF14, TNFSF9
T Cell Receptor Genes​
CD247, CD3D, CD3E, CD3G, TRAC, TRGC2
Major Histocompatibility Complex I Genes​
B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, MR1
Major Histocompatibility Complex II Genes​
CD74, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRA, HLA-DRB1, HLA-DRB5, IFI30
Other Checkpoint Molecules​
ADORA2A, BTNL2, CD160, CD276, CD44, CD52, CD8A, HHLA2, IDO1 (IDO), IDO1 (IDO), IDO2, KIR3DL1, KLRD1, LAIR1, MS4A1, NRP1, TIGIT, TMIGD2, TNFRSF25 (DR3), TNFRSF8, TNFSF15, VTCN1
Checkpoint Blockade Therapy Biomarkers
BTLA, CD274 (PD-L1), CD274 (PD-L1), CD80, CD8A, CSF2 (GM-CSF), CXCL11 (I-TAC, IP-9), HAVCR2, HLA-DRA, HLA-DRB1, HLA-DRB5, ICOS, IFNG, LAG3, PDCD1 (PD1), PDCD1 (PD1), PDCD1LG2
Immuno Regulatory Gene Signature
ERBB2 (HER-2, NEU), FAS, IL5RA (CD125), INHBA, TNFRSF8, TNFSF4 (OX40L), TNFSF9
Immuno Stimulatory Gene Signature
CD160, CD19, CD200, CD27 (TNFRSF7), CD44, CTLA4, HLA-A, IL12RB2, IL17A, KIT (CD117), TNFRSF17
Immuno Suppressive Gene Signature
CD274 (PD-L1), CD274 (PD-L1), CD276, HAVCR2, PDCD1LG2, TGFB1
Upregulated in Cancer Vaccination Response
CCL5 (RANTES), CD3D, CD86, CD8A, CXCL10 (INP10), CXCL9 (MIG), GBP1, ICOS, IRF1, KLRD1, PSMB9, STAT1
Immune Cell Markers
CD8 T Cells​
CD8A, CD8B, FLT3LG, GZMM, PRF1
Th1 Cells​
CCL4 (MIP-1B), CD38, CD70, CSF2 (GM-CSF), CTLA4, DPP4, IFNG, IL12RB2, LTA (TNFB), STAT4, TBX21
Th17 Cells​
IL17A, IL17RA, RORC
Th2 Cells​
CXCR6, GATA3, IL26, LAIR2, MAF, PMCH, SMAD2 (MADH2), STAT6
Follicular Helper T Cells​
BCL6, CXCL13, MAF, PDCD1 (PD1), PDCD1 (PD1)
Other T Helper Cell Markers​
ANP32B, BATF, CD28, ICOS, NUP107
Regulatory T Cells​
FOXP3
Gamma Delta T Cells​
CD160, FEZ1, TRGC1
Central Memory T Cells​
ATM, DOCK9, FYB1, NEFL, REPS1, TXK, USP9Y
Effector Memory T Cells​
AKT3, CCR2, EWSR1, IL15RA, LTK, NFATC4 (NFAT3)
Other T Cell Markers​
CD2, CD247, CD3D, CD3E, CD3G, CD6, IL2RB, TNFRSF25 (DR3), TRAC, TRGC2
Myeloid Derived Suppressor Cells​
TGFB1
Cytotoxic Lymphocytes​
CD3E, CD3G, CD8A, CD8B, EOMES, GZMA, GZMB, IFNG, KLRC1, KLRD1, NKG7, TBX21
Natural Killer Cells​
BCL2, CD160, FOXJ1, FUT5, GTF3C1, GZMB, IL21R, KIR3DL1, MPPED1, NCR1, PLA2G6, RRAD, ZNF205
Activated Dendritic Cells​
CCL1 (I-309), EBI3, LAMP3, OAS3
Immature Dendritic Cells​
CD1A, CD1B, CD1E, F13A1, SYT17
Myeloid Dendritic Cells​
CD1A, CD1B, CD1E
Plasmacytoid Dendritic Cells​
IL3RA
Other Dendritic Cell Markers​
CCL13 (MCP-4), CCL17 (TARC), CCL22 (MDC), CD209, HSD11B1
Macrophages​
APOE, CCL7 (MCP-3), CD68, CHIT1, CXCL5 (ENA-78, LIX), MARCO, MSR1
Neutrophils​
CSF3R (GM-CSFR), FPR2, MME
Eosinophils​
CCR3, IL5RA (CD125), PTGDR2 (CRTH2, GPR44), SMPD3, THBS1 (TSP-1)
Mast Cells​
CMA1, CTSG, KIT (CD117), MS4A2, PRG2, TPSAB1
B Cells​
BANK1, BLK, CD19, CD79A, CR2, HLA-DOB, HLA-DQA1, MS4A1, PAX5, TNFRSF17
Antigen Presenting Cells​
CMKLR1
Regulatory T Cell Gene Signature
CD274 (PD-L1), CD274 (PD-L1), JAK1, PDCD1LG2, TIGIT, TNFRSF18, TNFRSF4 (OX40), TNFRSF8, TNFRSF9
T Cell Trafficking & Infiltration into Tumors
Stimulates T Cell Trafficking & Infiltration into Tumors​
CCL5 (RANTES), CX3CL1, CXCL10 (INP10), CXCL9 (MIG), ITGB2, SELL (LECAM-1)
Other T Cell Trafficking & Infiltration into Tumors Genes​
CCL17 (TARC), CCL4 (MIP-1B), CCR3, CCR6, CD274 (PD-L1), CD274 (PD-L1), CD44, CSF2 (GM-CSF), CXCL11 (I-TAC, IP-9), CXCL13, FOXP3, IFNG, ITGA4 (CD49D), ITGB7, LTA (TNFB), PDCD1 (PD1), PDCD1 (PD1), PDCD1LG2, PTEN, TNFRSF25 (DR3), TNFSF14
T Cell Exhaustion
Upregulated in T Cell Exhaustion​
CCL5 (RANTES), CD200, CD27 (TNFRSF7), CD69, CTLA4, CXCL10 (INP10), CXCL13, GBP1, HLA-DMA, HLA-DQA1, ICOS, IFI16, IFNG, ITGAV, TAP1 (ABCB2), TIGIT, TNFRSF9
Downregulated in T Cell Exhaustion​
TNFRSF25 (DR3)
T Cell Exhaustion Transcriptional Nodes​
BATF, TBX21
Responsiveness or Response Biomarkers
Enhanced Expression in Responsive Versus Nonresponsive Cancers​
APP, CAPZB, CCL4 (MIP-1B), CCL5 (RANTES), CD8A, CSNK1E, CTLA4, CXCL10 (INP10), CXCL11 (I-TAC, IP-9), CXCL9 (MIG), EBI3, EHD1, GBA2, GZMB, HLA-DQA1, IDO1 (IDO), IDO1 (IDO), IFNG, INHBA, IRF2, NKG7, ODF2, PHKG2, PPIF, PRF1, SERPINA3, SHMT2, SIGMAR1, SMAD3 (MADH3), TIA1
Suppressed Expression in Responsive Versus Nonresponsive Cancers​
ACTG1, BNIP3L, CX3CL1, FOXN3, IFI27, JAK1, LTA4H, NAIP, OPTN, PRRC2B, PTEN, RBL2, TXK
Differentially Expressed in Responsive Versus Nonresponsive Cancers​
ADAM28, AKNA, AOAH, ARHGAP9, CACNA2D2, CARD11, CARD16, CD109, CLEC11A, CORO1A, CORO1B, CXCR4, FLT3, FMNL1, HIVEP1, HIVEP2, IFI44L, IFITM1 (9-27), IGHA1, IGHM, IGSF6, IKZF1, ITPKA, LSM4, LST1, MAP3K14, NFAM1, NFKBIL1, PLA2G2D, POU2AF1 (OCA-B), PTPRCAP, SERPINB9, SH3BP5, SYTL1, TMC8, TNFRSF13B, TNFRSF19, ZFYVE9
Expression Correlates with Positive Objective Response Rates​
CD274 (PD-L1), CD274 (PD-L1), CD276, CTLA4, HAVCR2, IDO1 (IDO), IDO1 (IDO), LAG3, PDCD1LG2, VTCN1
Upregulated during Treatment​
CD8A, CTLA4, CXCL10 (INP10), EOMES, GZMA, GZMB, ICOS, IFNG, PRF1
Regulated during Treatment​
IRF1
Pre-Treatment Response Prediction
Predicts Enhanced Response​
ADAM17 (CD156B), MYC, RHOC, TIMP1
Other Pre-Treatment Response Predictors​
CDK2, CDKN2A (P16INK4A), LARGE1, NAB2, NRAS
Cancer Cell Killing
Inhibits Cancer Cell Killing​
BTLA, CD274 (PD-L1), CD274 (PD-L1), CD80, HAVCR2, IDO1 (IDO), IDO1 (IDO), IDO2, LAG3, MICA, MICB, PDCD1 (PD1), PDCD1 (PD1), TGFB1, VSIR, VTCN1
Stimulates Cancer Cell Killing​
IFNG
Antigen Processing & Presentation
Proteasome​
PSMB10, PSMB9
Proteases​
IFI30
Endoplasmic Reticulum & Lysosomal Transport​
TAP1 (ABCB2), TAP2 (ABCB3), TAPBPL
Major Histocompatibility Complex I Genes​
B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, MR1
Major Histocompatibility Complex II Genes​
CD74, HLA-DMA, HLA-DQA1, HLA-DRA, HLA-DRB1, HLA-DRB5, IFI30
Immune Cell Receptors & Co-Receptors​
CD8A, CD8B, KIR3DL1, KLRC1, KLRD1
Stimulates Antigen Presentation​
CD40 (TNFRSF5), CD40LG
Interferon Gamma Response
Cytokines & Chemokines​
CCL5 (RANTES), IL15RA, STAT1
Major Histocompatibility Complex I Genes​
B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H
Major Histocompatibility Complex II Genes​
HLA-DMA, HLA-DQA1, HLA-DRA, HLA-DRB1, HLA-DRB5, IFI30
RNA Degradation​
OAS3
Transcription Factors​
IRF1, IRF2
Other Interferon Gamma Response Genes​
CD44, GBP1
Cytosolic DNA-Sensing Pathway
Cytokines & Interferons​
CCL4 (MIP-1B), CCL5 (RANTES), CXCL10 (INP10)
Oncogenes
AKT1, ALK, BRAF, CTNNB1, EGFR (ERBB1), ERBB2 (HER-2, NEU), FOXL2, GNA11, GNAQ, IDH1, IDH2, KIT (CD117), KRAS, MET, NRAS, PDGFRA, PIK3CA (p110-alpha), RET
Cell Adhesion Molecules
CTNNB1, EGFR (ERBB1), ERBB2 (HER-2, NEU), PDGFRA, RET
Angiogenesis
CTNNB1, ERBB2 (HER-2, NEU), PIK3CA (p110-alpha)
Apoptosis
BRAF, CTNNB1, FOXL2, RAF1
Cell Cycle
AKT1
Immune Response
ALK, PIK3CA (p110-alpha)
Metabolism
IDH1, IDH2
Signal Transduction:
AKT & PI3 Kinase Signaling​
AKT1, ERBB2 (HER-2, NEU), KIT (CD117), PDGFRA, PIK3CA (p110-alpha)
Fibroblast Growth Factor Signaling​
AKT1, PIK3CA (p110-alpha)
G-Protein Coupled Receptor Signaling​
AKT1, GNA11, GNAQ
Hormone Receptors​
ESR1 (ERα)
MAP Kinase Signaling​
NRAS, RAF1
Receptor Tyrosine Kinases​
ALK, EGFR (ERBB1), ERBB2 (HER-2, NEU), ERBB3, KIT (CD117), PDGFRA, RET
WNT Signaling​
CTNNB1
Other Signal Transduction Genes​
KRAS, MET
Transcription Factors
ESR1 (ERα), FOXL2
Gene Resource List
Detailed Target List for each Analyte
File Size: 38.89 KBLanguage: English

Resources

Kit Handbooks (1)
Template Files (1)
Certificates of Analysis (1)
Introducing the RNA Fusion XP Solid Tumor Panel, a cutting-edge addition to our QIAseq RNA Fusion XP Panels lineup, specifically designed for {{application}} applications. This premium product offers unparalleled performance for researchers working with Human models. Leveraging advanced technology, the RNA Fusion XP Solid Tumor Panel facilitates accurate and reliable results, making it an indispensable tool for your scientific investigations. Whether you're conducting {{application}}, or any other sophisticated analyses, this product from our QIAseq RNA Fusion XP Panels collection ensures optimal efficiency and reproducibility for Human studies. Embrace the future of research with RNA Fusion XP Solid Tumor Panel and elevate your work to new heights.